查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869957

抗精神病藥物市場規模、佔有率和趨勢分析報告：按疾病、藥物、治療類別、分銷管道、地區和細分市場預測（2025-2033 年）

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

抗精神病藥物市場摘要

2024年全球抗精神病藥物市場規模估計為175.3億美元，預計2033年將達到322.4億美元。

預計2025年至2033年間，該市場將以6.1%的複合年成長率成長。市場擴張主要歸因於精神疾病盛行率的上升、公眾意識的提高以及技術創新。政府支持、保險覆蓋範圍的擴大以及學名藥的廣泛普及，進一步提高了藥物的可及性，尤其是在新興市場。

抗精神病藥物（也稱為阻斷劑）常用於緩解精神病相關症狀。抗精神病藥物能有效減輕和控制多種症狀，包括妄想和幻聽（聽到聲音）。其作用機制是透過抑制大腦中多巴胺和其他神經傳導物質的活性。目前市面上已有第一代和第二代抗精神病藥物。

精神病性障礙盛行率的不斷上升預計將推動抗精神病藥物行業的需求。思覺失調症在男性中的盛行率始終高於女性，隨著各地預期壽命的延長，思覺失調症的整體負擔預計將進一步加重。人口老化也是支撐需求的因素之一，因為諸如失智症相關精神病等疾病變得越來越常見。新型製劑和具有全新作用機制的藥物獲得監管部門核准，克服了傳統療法的局限性，進一步促進了市場成長。

科技進步與研發的推動，促使新型、更有效的抗精神病藥物不斷湧現。製藥公司正大力投資研發副作用更少、療效更佳、患者依從性更高的藥物。 2025年9月，H. Lundbeck和Otsuka Holdings Co., Ltd.收到了美國食品藥物管理局（FDA）的完整回覆函（CRL），該函針對的是Rexulty（Brexpiprazole）和舍曲林聯合治療接受成人創傷後壓力症候群（PTSD）的補充新藥認證申請（sNDA）。

Eisai的阿茲海默症治療核准Rekemvi於2023年1月核准。神經系統疾病先進治療方案的引入導致全球患者使用抗精神病藥物的情況增加。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 抗精神病藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗精神病藥物市場分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析

第4章：抗精神病藥物市場：依疾病區分的估算與趨勢分析

  • 疾病細分儀表板
  • 抗精神病藥物市場：按疾病分類的變化分析
  • 全球抗精神病藥物市場規模及趨勢分析（依疾病分類，2021-2033 年）
    • 思覺失調症
    • 躁鬱症
    • 單相憂鬱症
    • 失智
    • 其他

第5章：抗精神病藥物市場：藥物具體估算與趨勢分析

  • 藥品細分儀表板
  • 抗精神病藥物市場：按藥物分類的波動分析
  • 全球抗精神病藥物市場規模及趨勢分析（按藥物分類，2021-2033 年）
    • Risperidone
    • Quetiapine
    • Olanzapine
    • Aripiprazole
    • Brexpiprazole
    • 棕櫚酸帕利哌酮
    • 其他

第6章：抗精神病藥物市場：依治療層級的估算與趨勢分析

  • 治療層級細分儀表板
  • 抗精神病藥物市場：依治療類別分析變化
  • 全球抗精神病藥物市場規模及趨勢分析（按治療層級，2021-2033 年）
    • 第一代
    • 第二代
    • 第三代

第7章：抗精神病藥物市場：按分銷管道分類的估算和趨勢分析

  • 分銷通路細分儀表板
  • 抗精神病藥物市場：按分銷管道分析波動情況
  • 全球抗精神病藥物市場規模及趨勢分析（按分銷管道分類，2021-2033 年）
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第8章：抗精神病藥物市場：區域估算與趨勢分析

  • 區域市場概覽
  • 2024 年及 2033 年區域市佔率分析
  • 區域市場：主要結論
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
  • 公司簡介
    • H. Lundbeck A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Janssen Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Dr Reddy's Laboratories Ltd.
    • Sumitomo Pharma Co., Ltd.
    • Alkermes
    • Bristol-Myers Squibb Company
Product Code: GVR-1-68038-408-6

Antipsychotic Drugs Market Summary

The global antipsychotic drugs market size was estimated at USD 17.53 billion in 2024 and is projected to reach USD 32.24 billion by 2033, growing at a CAGR of 6.1% from 2025 to 2033. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations. Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets.

Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • Paliperidone Palmitate
  • Others
  • Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)
  • First Generation
  • Second Generation
  • Third Generation
  • Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug
    • 1.2.3. Therapeutic class
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Drug outlook
    • 2.2.3. Therapeutic class
    • 2.2.4. Distribution Channel
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Antipsychotic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

  • 4.1. Disease Segment Dashboard
  • 4.2. Antipsychotic Drugs Market: Disease Movement Analysis
  • 4.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
    • 4.3.1. Schizophrenia
      • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.2. Bipolar Disorder
      • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.3. Unipolar Depression
      • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.4. Dementia
      • 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drugs Estimates & Trend Analysis

  • 5.1. Drugs Segment Dashboard
  • 5.2. Antipsychotic Drugs Market: Drug Movement Analysis
  • 5.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Drugs, 2021 to 2033 (USD Million)
    • 5.3.1. Risperidone
      • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Quetiapine
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3. Olanzapine
      • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.4. Aripiprazole
      • 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.5. Brexpiprazole
      • 5.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.6. Paliperidone Palmitate
      • 5.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.7. Others
      • 5.3.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 6.1. Therapeutic Class Segment Dashboard
  • 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis
  • 6.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Therapeutic Class, 2021 to 2033 (USD Million)
    • 6.3.1. First Generation
      • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.2. Second Generation
      • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.3. Third Generation
      • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis
  • 7.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    • 7.3.1. Hospital Pharmacies
      • 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Retail Pharmacies
      • 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Online Pharmacies
      • 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Regional Market Share Analysis, 2024 & 2033
  • 8.3. Continuous bioprocessing market by Region: Key Takeaways
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Denmark
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory framework/ reimbursement structure
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company heat map analysis, 2024
  • 9.4. Company Profiles
    • 9.4.1. H. Lundbeck A/S
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Otsuka Pharmaceutical Co., Ltd.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Janssen Pharmaceuticals, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. AbbVie, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Teva Pharmaceutical Industries Ltd.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Dr Reddy's Laboratories Ltd.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Sumitomo Pharma Co., Ltd.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Alkermes
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antipsychotic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 4 Global antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 5 Global antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 6 Global antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 9 North America antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 10 North America antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 11 North America antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 U.S. antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 13 U.S. antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 14 U.S. antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 15 U.S. antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 16 Canada antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Canada antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 18 Canada antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 19 Mexico antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 20 Mexico antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 21 Mexico surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 22 Mexico antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 23 Europe antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 24 Europe antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 25 Europe antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 26 Europe antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 27 Europe antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 UK antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 29 UK antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 30 UK antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 31 UK antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Germany antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 33 Germany antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 34 Germany antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 35 Germany antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 France antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 37 France antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 38 France antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 39 France antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 40 Italy antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 41 Italy antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 42 Italy antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 43 Italy antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 44 Spain antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 45 Spain antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 46 Spain antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 47 Spain antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Denmark antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 49 Denmark antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 50 Denmark antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 51 Denmark antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Sweden antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 53 Sweden antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 54 Sweden antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 55 Sweden antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Norway antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 57 Norway antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 58 Norway antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 59 Norway antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Japan antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Japan antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 67 Japan antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 68 Japan antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 69 China antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 70 China antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 71 China antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 72 China antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 73 India antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 74 India antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 75 India antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 76 India antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Australia antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 78 Australia antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 79 Australia antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 80 Australia antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 81 South Korea antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 82 South Korea antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 83 South Korea antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 84 South Korea antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 85 Thailand antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 86 Thailand antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 87 Thailand antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 88 Thailand antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 89 Latin America antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 90 Latin America antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 91 Latin America surgical ablation market, by drug, 2021 - 2033 (USD Million)
  • Table 92 Latin America laparoscopic ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 93 Latin America percutaneous ablation market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 94 Brazil Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 95 Brazil Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 96 Brazil surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 97 Brazil antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 98 Argentina Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 99 Argentina Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 100 Argentina surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 101 Argentina antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 102 MEA Antipsychotic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 103 MEA Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 104 MEA Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 105 MEA Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 106 MEA antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 107 South Africa Antipsychotic drugs market, by Disease, 2021 - 2033 (USD Million)
  • Table 108 South Africa Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 109 South Africa Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 110 South Africa antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 115 UAE Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 116 UAE Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 117 UAE Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 118 UAE antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 119 Kuwait Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 122 Kuwait antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Antipsychotic drugs market: market outlook
  • Fig. 10 Antipsychotic drugs: Competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Antipsychotic drugs market driver impact
  • Fig. 16 Antipsychotic drugs market restraint impact
  • Fig. 17 Antipsychotic drugs market strategic initiatives analysis
  • Fig. 18 Antipsychotic drugs market: disease movement analysis
  • Fig. 19 Antipsychotic drugs market: disease outlook and key takeaways
  • Fig. 20 Schizophrenia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Bipolar disorder market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Unipolar depression market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Dementia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Antipsychotic drugs market: Drug movement Analysis
  • Fig. 26 Antipsychotic drugs market: Drug outlook and key takeaways
  • Fig. 27 Schizophrenia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Bipolar disorder market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 29 Unipolar depression market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 30 Dementia market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 31 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Antipsychotic drugs market: Therapeutic class movement analysis
  • Fig. 33 Antipsychotic drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 34 First-generation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Second-generation market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 36 Third-generation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Antipsychotic drugs market: Distribution channel movement analysis
  • Fig. 38 Antipsychotic drugs market: Distribution channel outlook and key takeaways
  • Fig. 39 Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Retail pharmacies market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 41 Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Global antipsychotic drugs market: Regional movement analysis
  • Fig. 43 Global antipsychotic drugs market: Regional outlook and key takeaways
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)